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Summary We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP,
ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific
enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated
patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung
diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent
assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area
under curve (AUC) of 'receiver operator characteristics' of ProGRP(31 -98) with that of NSE, ProGRP(31-
98) was the more powerful marker in the diagnosis of SCLC (P=0.0001). Serum levels of ProGRP(31-98)
were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P=0.0082).
ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed
small-cell/large-cell carcinoma (P=0.02). In serial measurement in 16 patients responding to treatment, a high
degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response
during the second week after treatment (P=0.0045). These results indicate that the determination of serum
ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.
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A number of serum components have been Proposed as
markers of the extent of disease and of the clinical response
to cytotoxic therapy in patients with small-cell lung cancer
(SCLC) (Bates and Longo, 1987). Among these, neuron-
specific enolase (NSE) has been Proved sufficiently sensitive
and specific for general use in the diagnosis and management
of these patients (Akoun et al., 1985; Ariyoshi et al., 1983;
Carney et al., 1982; Cooper et al., 1985; Esscher et al., 1985;
Nou et al., 1990). However, studies on NSE have shown a
number of weaknesses with respect to its specificity for
SCLC; these include a relatively high false-positive rate in
patients with non-malignant lung diseases (Esscher et al.,
1985) and non-small-cell lung cancer (NSCLC) (Ariyoshi et
al., 1983; Cooper et al., 1985; Esscher et al., 1985; Notomi et
al., 1985) and an increase in levels by haemolysis (Esscher et
al., 1985; Notomi et al., 1985). Accordingly, a more specific
tumour marker that can reliably and rapidly reflect the
diagnosis and efficacy of treatment for patients with SCLC
has been sought.
McDonald et al. (1978) isolated a 27 amino acid peptide
homologous to the carboxy-terminal of bombesin from
porcine stomach and named this compound gastrin-releasing
peptide (GRP). Spindel et al. (1984) prepared and cloned
cDNAs derived from mRNA from a human pulmonary
carcinoid tumour that had strong immunoreactivity to GRP.
A number of investigators have reported that immunoreac-
tive GRP is present in the fetal and neonatal lung (Wharton'
et al., 1978; Yamaguchi et al., 1983) and in primary lung
cancer, especially in SCLC (Erisman et al., 1982; Moody et
al., 1981; Wharton et al., 1978). Additionally, immunohisto-
chemical analysis (Cuttitta et al., 1988) of ProGRP fragments
(GGAPs) was also reported to immunostain both GRP and
GGAP in SCLC cell lines and human SCLC tumours. This
finding suggested the possibility that the plasma GRP level
could serve as a marker of SCLC. ProGRP(31-98), a region
common to the three types of previously cloned human
ProGRP molecules, has recently been synthesised (Aoyagi et
al., 1995; Miyake et al., 1994). Aoyagi et al. (1995) have now
developed a highly sensitive ELISA system which detects
serum immunoreactive ProGRP(31-98).
The present study was undertaken to identify the
relationship between this marker and other clinical factors
in SCLC. In addition, we compared its discriminatory power
with that of NSE, the marker presently used for SCLC.
Materials and methods
Patients
A total of 212 consecutive samples (Table I) of frozen serum
stored at -80°C were retrospectively examined. All patients
had been referred to the Osaka Prefectural Habikino
Hospital between April 1990 and June 1994, where lung
cancer was pathologically confirmed. They had received no
prior treatment with chemotherapy, radiotherapy or surgery.
Patients studied included 101 with SCLC and 111 with
NSCLC, comprising 46 with adenocarcinoma, 48 with
squamous cell carcinoma and 17 with large-cell lung
carcinoma. Performance status was estimated according to
the Eastern Cooperative Oncology Group (ECOG) scale.
Patients were staged with routine chest radiography,
computerised tomography of the chest, brain and upper
abdomen, fibre optic bronchoscopy, and radionuclide bone
scans. Patients with SCLC also underwent bilateral bone
marrow aspiration cytology. NSCLC was staged according to
the tumour-node-metastasis system (Mountain, 1986).
Staging of SCLC was established according to the IASLC
recommendation (Stahel et al., 1989); limited disease was
defined as disease confined to one hemithorax with or
without ipsilateral or contralateral mediastinal or supraclavi-
cular lymph node metastasis. All other disease was classified
as 'extensive disease'. Cases of pleural effusion were classified
as limited disease regardless of cytology (Stahel et al., 1989).
Response was classified during regular meetings of the group
in accordance with the World Health Organization (WHO)
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Table I Patient characteristics
Non-malignant
Lung cancer lung disease
Number 212 114
Male/female 164/48 71/43
Median age (range) 66 (43-83) 59 (13-90)
PS 0,1/2,3 140/72
Histology
SCLC 101 CPE 10
NSCLC 111 lIP 14
Adenocarcinoma 46 HP 7
Squamous cell carcinoma 48 BA 20
Large-cell carcinoma 17 Pneumonia 6
Stage Bronchitis 2
SCLC Tuberculosis 35
Limited disease 61 Others 20
Extensive disease 40
NSCLC
1,11 16
IIIA 22
IIIB 39
IV 34
SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer;
CPE, chronic pulmonary emphysema; IIP, idiopathic interstitial
pneumonia; HP, hypersensitivity pneumonitis; BA, bronchial asthma.
criteria (Miller et al., 1981). Informed consent as to the
investigational nature and the sequential measurement of
ProGRP(31-98) and NSE was obtained from 16 patients.
All patients with SCLC received one of the combination
chemotherapy regimens: PE (cisplatin +etoposide) with or
without thoracic irradiation for 40 patients; CODE
(cisplatin +vincristine +doxorubicin +etoposide) (Murray et
al., 1991) for 22 patients; carboplatin +etoposide for 19
patients; CPT-11-containing regimen (Fujiwara et al., 1994;
Masuda et al., 1992) for 11 patients; CAV (cyclopho-
sphamide +doxorubicin +vincristine)-PE (Fukuoka et al.,
1991).
Controls
Control blood samples were obtained during routine
haematology from 114 patients attending our hospital for a
variety of non-malignant lung disease (Table I). Diagnoses in
these patients were established on the basis of clinical,
radiological and laboratory criteria.
ProGRP(31-98) and NSE enzyme immunoassay
The assay for ProGRP(31 -98) was carried out with a
sandwich ELISA system to be reported by Aoyagi et al.
(1995). Briefly, microtitre plate wells were coated with anti
ProGRP(31-98) mouse monoclonal antibody. To each well
was added 100 ,ul per well of reaction buffer, then 50 MI per
well of human sera or standard ProGRP(31-98). The
reaction mixture was incubated for 1 h at 37°C. The plates
were washed and horseradish peroxidase-conjugated rabbit
polyclonal antibody was added to each well and further
incubated for 30 min at room temperature. After the plates
were washed again, the colour of the enzyme reaction was
developed by the addition of substrate solution containing
o-phenylenediamine plus hydrogen peroxide, and stopped by
adding 4 M sulphuric acid. The absorbance of each well at
492 nm was measured by a Corona MTP-32 microplate
reader (Conona Electric, Ibaraki, Japan). The variability and
accuracy of this assay will be described by Aoyagi et al.
(1995). Briefly, this ELISA for ProGRP(31-98) can easily be
measured within about 2 h in clinical use. The coefficients of
variation for intra-assay precision and interday reProduci-
bility in a panel of sera both ranged from 1.7% to 6.8%
respectively. No interference was seen from blood elements in
serum or anticoagulants, nor was any cross-reactivity with
GRP, bombesin, neurokinin A, galanin, calcitonin gene-
related peptide, adrenocorticotropic hormone or NSE seen at
a concentration of 1 ,ug ml-1 for each. NSE levels were
determined by a sandwich enzyme immunoassay as described
by Ishiguro et al. (1982). All serum samples were assayed
blind of clinical information.
Histological diagnosis
The primary diagnosis of SCLC was made on materials
obtained by bronchoscopy, mediastinoscopy and/or scalene
node biopsy. All diagnostic materials were reviewed by one of
the authors. Diagnostic criteria for SCLC were those of the
current IASCL classification (Hirsch et al., 1988). The
diagnosis of SCLC was made on cytological materials as
well as histological materials, but morphological suibclassifi-
cation was made only on the histological materials. All slides
from patients with mixed small-cell/large-cell carcinoma for
this analysis were reviewed independently by two patholo-
gists, who agreed on the diagnosis for each patient.
Statistical analysis
Data were represented as median and the 90th and 75th
percentiles of variability. All data other than those of the
receiver operator characteristics (ROC) curves were analysed
by non-parametric methods. The Mann-Whitney U-test was
used for the comparison of two groups of random samples.
Multiple comparisons were performed with the Kruskal-
Wallis one-way analysis. To evaluate the accuracy of the two
different markers, the areas under the two ROC curves were
statistically compared using a univariate z-score test by the
CLABROC Program (Metz, 1991). To compare the levels of
markers before and after treatment, the Wilcoxon single-rank
test was used. Percentages in different groups were compared
using the chi-square test.
ROC curves, which correlate with the true- and false-
positive rate (sensitivity and 1 minus specificity respectively),
were constructed using the CLABROC Program (Metz, 1991)
in an attempt to compare the accuracy of ProGRP(31-98)
and NSE. In addition, the areas under the curves of the two
markers were calculated and analysed using the same
Program. This Program calculates maximum likelihood
estimates of the parameters of a 'bivariate binormal' model
for continuously distributed data from two potentially
correlated diagnostic tests. It thus estimates the binormal
ROC curves implied by those data and their correlation, and
also calculates the statistical significance between the two
ROC curves estimated using a univariate z-score test of the
difference between the area under the two ROC curves. The
CLABROC algorithm, developed by Professor CE Metz at
the University of Chicago, is a version of the CORROC
algorithm (Metz et al., 1984) that has been modified to
analyse continuously distributed data (Metz et al., 1990).
Results
Cut-off value calculation
In order to compare our results for the different tumour
markers under the same conditions we followed the
recommendations of the 'Hamburg Group for the Standardi-
sation of Tumour Markers' (Klapdor, 1992). Cut-off values
for each reference group were fixed at a specificity of 95%.
Thus, in 95% of the non-malignant lung diseases,
ProGRP(31 -98) values were below 33.8 pg ml- and NSE
values were below 10.6 ng ml- .
Tumour marker distribution and diagnostic sensitivity
The distribution of ProGRP(31-98) and NSE concentrations
in regard to the histological types of lung cancer and non-
malignant lung diseases is illustrated in Figure 1. The median
(interquartile range) values of serum ProGRP(31 -98) forProGRP(31-98) as a tumour marker of SCLC
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* ProGRP
O NSE
AUC of proGRP (31-98) = 0.94 ± 0.015
NSE = 0.81 ± 0.032
P-value = 0.0001
False-positive rate
Figure 2 Receiver operator characteristics (ROC) curves in
small-cell lung cancer. Curves were constructed using the
CLABROC program and show that proGRP(31-98) is a specific
tumour marker for the diagnosis of small-cell lung cancer. AUC,
area under curve.
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Figure 1 Distribution of individual serum (a) ProGRP(31-98)
and (b) neuron-specific enolase values in lung cancer and non-
malignant lung disease. Data are presented as a box (upper and
lower quartile and range), median value (horizontal line) and
whisker line showing the middle 90 per cent distribution. SCLC,
small-cell lung cancer; NSCLC, non-small-cell lung cancer.
SCLC, NSCLC and non-malignant lung diseases were 234.4
(31.7-894.8), 22.6 (17.7-30.2) and 12.4 (9.5-18.6) pg ml-'
respectively. This ProGRP(31-98) level in SCLC was
significantly different (P=0.0001) from that in NSCLC and
benign lung diseases. Serum ProGRP(31-98) levels were
significantly higher in SCLC than in NSCLC (P=0.0001).
Based on a specificity of95% vs non-malignant lung diseases,
ProGRP(31-98) showed a true-positive test result in 72.3%
of SCLC and 14.4% of NSCLC cases. In contrast, NSE
showed a true-positive result in 62.4% of SCLC and 33.3%
of NSCLC cases.
Area under ROC curves for the tumour markers
To confirm the correlations of true- and false-positive rates
(sensitivity and 1 minus specificity, respectively) for a series of
cut-off points for any test, ROC curves for ProGRP(31-98)
and NSE in SCLC were prepared (Figure 2). Calculation of
areas under the ROC curves using the CLABROC Program
showed a significant difference between the two markers
(P =0.0001).
ProGRP and NSE by clinical stage at presentation
ProGRP(31-98) levels were analysed according to stage.
Median and interquartile range of serum ProGRP(31-98)
and NSE according to stage are shown in Table II.
Significantly higher ProGRP(31-98) levels were observed in
patients with extensive SCLC than in those with limited
disease (P =0.0082). NSE levels were also significantly higher
in patients with extensive SCLC than in those with limited
SCLC (P=0.0045). Positive rates of ProGRP(31-98) were
67.2% in 61 limited and 80% in 40 extensive cases (P= 0.24).
In contrast, positive rates of NSE were 50.8% and 80%
respectively (P = 0.006).
Table II Serum ProGRP(31-98) and NSE levels according to clinical and histological variables in patients with SCLC
ProGRP(31-98)- NSEb
Median Rangec P-valued Median Rangec P-valued
Stage 0.0082 0.0045
Limited disease (n=61) 120.7 26.2-604.8 11.5 5.3-29.5
Extensive disease (n=40) 556.6 98.6-3132 20.9 12.1-41.3
Number of metastatic sites 0.22 0.4
1 (n=29) 493.9 31.2-2565 21.2 11.5-40
>2 (n=11) 887.6 286.4-9565 19.7 13.9-68.3
Metastatic sites 0.92 0.93
Liver (n=10) 597 255.1-2536 20.5 12.7-42.2
Bone marrow (n =10) 803.1 493.9-2652 20.5 12.1 -40.3
Bone (n=7) 887.6 99.2-2931 39.9 13.9-55.4
Brain (n=7) 587.6 130.5-5141.1 17.6 8.8-40.8
apg ml-1. bng ml-. cInterquartile range. dP-values were determined using the Mann-Whitney U-test. P-value in the differences according to
metastatic sites was determined using the Kruskal-Wallis test.
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ProGRP and NSE levels according to metastases
The relationship of serum ProGRP(31-98) levels to the site
of metastasis and to the number of metastasised organs was
analysed (Table II). Although ProGRP(31-98) levels in the
40 patients with extensive SCLC were higher in the 11
patients who had two or more metastatic sites than in the 29
who had only one site, there was no significant difference
between the groups (P=0.22). The same trend was seen for
NSE (P=0.40).
In addition, the relationship between raised tumour
marker levels and the site of metastasis was analysed for 40
patients in whom a dominant site could be clearly
established, namely in the liver, bone marrow, brain and
bone in 10 (25%), 10 (25%), 7 (17.5%) and 7 (17.5%)
patients respectively (Table II). Serum ProGRP(31-98) and
NSE levels did not differ significantly when metastatic site
was considered (P=0.92 in ProGRP(31 -98), P=0.93 in
NSE).
ProGRP and NSE according to SCLC subtype
SCLC was classified in 11 of 101 SCLC patients without
further subtyping because the histological materials were
crushed or only cytological materials were available for
diagnosis. This left 90 patients for morphological subtyping.
Seventy-nine of the 90 patients (87.8%) were classified as
having pure small-cell carcinoma, namely the oat cell type in
45, intermediate cell type in 16 and mixtures of these types in
18. Ten patients were classified as having the mixed small-
cell/large-cell carcinoma, and one had the small-cell type
combined with adenocarcinoma. The distribution of
ProGRP(31-98) levels according to SCLC subtype are
shown in Figure 3. ProGRP(31 -98) levels were significantly
higher in pure small-cell carcinoma (median, 290.2; inter-
quartile range, 36.6-888.2 pg ml-') than in small-cell/large-
cell carcinoma (median, 21.9; interquartile range, 18.8-
47.2 pg ml-'; P= 0.02). In contrast, there was no significant
difference (P=0.06) in NSE levels between the pure small-cell
carcinoma and the mixed small-cell/large-cell form.
Correlation between serialplasma ProGRP(31-98) levels and
response to therapy
Serial ProGRP(31-98) and NSE levels obtained during
induction therapy were evaluated in 16 patients (Figure 4).
All patients responded to treatment, two achieving a
complete response and 14 a partial response. Ten of these
patients had initial ProGRP(31-98) levels greater than
33.8 pg ml-'. These patients all showed a marked decrease
in ProGRP(31-98) level after treatment, with values on day
14 significantly decreased compared with pretreatment levels
(Wilcoxon; P=0.0045). On a semilog plot, these decreases
were almost linear within 2 weeks after treatment. However,
there was no clear correlation between serial serum NSE level
and response to treatment.
In three patients with positive pretreatment ProGRP(31-
98) and NSE levels, these levels at the time of clinical relapse
were determined. In one patient (Figure 4, patient A), only
ProGRP was rising before clinical detection of Progression.
Discussion
In our series, raised ProGRP(31-98) levels were found at
diagnosis in 72.3% of SCLC patients and 14.4% of NSCLC
patients. In contrast, NSE showed a true-positive result in
62.4% of SCLC patients and 33.3% of NSCLC patients.
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When two or more tests are available in the pursuit of
diagnostic considerations, comparison of the 'receiver
operating characteristic' (ROC) of each will often show
where one has an advantage over the other. On the basis of
our results for area under the curve (AUC) of each ROC
(Figure 2), ProGRP(31-98) was more specific than NSE in
the diagnosis of SCLC. Others have reported similar results.
Miyake et al. (1994) reported the good specificity and
sensitivity Profile of ProGRP(31 -98) in the diagnosis of
SCLC patients using radioimmunoassay (RIA). Furthermore,
Holst et al. (1989) reported using RIA that 72% of 71 SCLC
patients had elevated levels of a fragment of ProGRP
corresponding to the 42-53 sequence.
Although positive rates of both ProGRP(31-98) and NSE
increased as the stage of disease Progressed, the difference
was more significant for NSE. This may be a reflection of the
high positive rate of 67.2% for ProGRP(31-98) in limited
stage SCLC. In the report of Miyake et al. (1994), serum
ProGRP(31-98) levels were elevated at almost the same
frequency in patients with limited SCLC as in those with
extensive disease indicating that serum ProGRP(31-98) level
could serve as a reliable tumour marker in SCLC patients
even at a relatively early stage of the disease. In addition,
serum ProGRP(3 1-98) levels in our patients with SCLC
were highly elevated in patients with metastases at two or
more sites (Table II). This finding may indicate the existence
of a correlation between tumour burden and serum
ProGRP(31-98) level.
Carney and colleagues (1985) identified several biomarkers
in cell lines of SCLC including L-dopa decarboxylase (DDC),
NSE, GRP and BB isozyme of creatine kinase (CK-BB). In
further analysis, classic SCLC lines of histologically pure
small-cell carcinoma expressed elevated levels of all four
biomarkers. In contrast, variant SCLC lines of histologically
mixed small-cell/large-cell carcinoma had undetectable levels
of DDC and GRP, but continued to express NSE and CK-
BB. Our results seem to correlate well with these results in
SCLC cell lines, namely that ProGRP(31-98) levels are low
and NSE levels relatively high in patients with mixed small-
cell/large-cell carcinoma (Figure 3). Another interesting
finding in our study was the detection of a minor elevation
in ProGRP(31-98) level in some patients with mixed small-
cell/large-cell carcinoma. As suggested by Holst et al. (1989),
the reason for this may be that tumour-derived GRP is
metabolised so quickly that it escapes detection (Knigge et
al., 1984) whereas ProGRP(31-98) might survive longer in
the circulation.
Although we did not analyse serum ProGRP(31-98) levels
in patients with neuroendocrine lung tumours except SCLC,
Yamaguchi et al. (1983) reported that immunoreactive GRP
was found in five of the 12 bronchial carcinoid tumours
(42%). Therefore, we speculate that the elevation of serum
ProGRP(31-98) levels in bronchial carcinoid tumours would
be also indicated at the rate like GRP in terms of concordant
expression of GRP and ProGRP(31-98).
In serial determinations of serum ProGRP(31-98) level, a
significant decrease in ProGRP(31 -98) occurred within 2
weeks after treatment even when a major response was not
observed (Figure 4). Furthermore, these decreases in
ProGRP(31 -98) levels were linear on the semilog plot
within 2 weeks after treatment (Figure 4). Miyake et al.
(1994) also demonstrated an excellent correlation between
ProGRP(31-98) level and therapeutic response. Although
they measured levels only twice, before and at 1 month after
therapy, levels had decreased by the second measurement to
an undetectable range in all cases showing a complete
response and in one-third of cases showing a partial
response. These findings indicate that the monitoring of
ProGRP(31-98) level during induction treatment will allow
both the prediction and confirmation of tumour response.
Furthermore, if ProGRP(31 -98) levels reflect the actual
tumour burden, the decreasing pattern illustrated in Figure 4
may show a log reduction in the number of tumour cells by
cytotoxic treatment. However, the number of our follow-up
cases was too small to lead to a conclusion for monitoring,
therefore we recently conducted a Prospective trial to
monitor this marker.
The usefulness of ProGRP(31-98) as the indicator of
early relapse was not shown in our small number of patients
with the long-term follow-up for this marker. However, the
early detection ofrelapsing SCLC would not offer advantages
to the patient, because the therapeutic measures in case of
relapse are still rather limited.
The practical value of a tumour marker is determined by
three factors: the frequency with which the marker is detected
in the tumour population; the correlation between the blood
level of the marker and the tumour burden; and the
availability of effective treatment for the tumour (McKenzie
et al., 1977). Data from our study suggest that ProGRP(31 -
98) apProaches these criteria as a tumour marker of value in
the diagnosis and treatment planning of SCLC.
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